Menu Search
Equities

Novacyt SA

NCYT:LSE

Novacyt SA

Actions
Health CareMedical Equipment and Services
  • Price (GBX)52.10
  • Today's Change-0.600 / -1.14%
  • Shares traded145.59k
  • 1 Year change-6.63%
  • Beta--
Data delayed at least 20 minutes, as of Nov 08 2024 16:22 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Income statement information is not available for Novacyt SA.
Gross margin153.78%
Net profit margin-201.27%
Operating margin-205.93%
Return on assets-32.27%
Return on equity-42.04%
Return on investment-38.44%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at Novacyt SA fell by 42.92m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 24.99m for operations while cash used for investing totalled 13.94m.
Cash flow per share-0.5239
Price/Cash flow per share--
Book value per share1.20
Tangible book value per share0.6868
More ▼

Balance sheet in GBPView more

Novacyt SA has a Debt to Total Capital ratio of 15.73%, a higher figure than the previous year's 0.20%.
Current ratio4.04
Quick ratio3.82
Total debt/total equity0.1867
Total debt/total capital0.1573
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.